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Abstract
Multiple sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system. However, studies of MS and
the animal model, experimental autoimmune encephalomyelitis (EAE), indicate that neuronal pathology is the principle
cause of clinical disability. Thus, there is need to develop new therapeutic strategies that not only address
immunomodulation but also neuroprotection. Here we show that the combination therapy of Glatiramer acetate (GA),
an immunomodulatory MS therapeutic, and the neuroprotectant epigallocatechin-3-gallate (EGCG), the main phenol in
green tea, have synergistic protective effects in vitro and in the EAE model. EGCG and GA together led to increased
protection from glutamate- and TRAIL-induced neuronal cell death in vitro. EGCG combined with GA induced regeneration
of hippocampal axons in an outgrowth assay. The combined application of EGCG and GA did not result in unexpected
adverse events in vivo. Neuroprotective and neuroregenerative effects could be translated in the in vivo model, where
combination treatment with EGCG and GA significantly delayed disease onset, strongly reduced clinical severity, even after
onset of symptoms and reduced inflammatory infiltrates. These results illustrate the promise of combining neuroprotective
and anti-inflammatory treatments and strengthen the prospects of EGCG as an adjunct therapy for neuroinflammatory and
neurodegenerative diseases.
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Introduction
Multiple Sclerosis (MS) is a common inflammatory autoim-
mune disease of the central nervous system (CNS) in which
myelin-specific CD4+Th1 and Th17 cells are thought to
orchestrate effector processes resulting in the destruction of the
myelin sheath [1]. Recent studies in MS and the animal model,
experimental autoimmune encephalomyelitis (EAE) suggest that
already during the early phase of disease, neuronal pathology
involving axonal transection and loss of parental cell bodies play a
pivotal role in clinical severity and correlate better with long-term
disability than the degree of demyelination [2,3,4]. Regarding the
underlying mechanisms, we showed that tumor necrosis factor
related apoptosis inducing ligand (TRAIL) contributes to
inflammatory neurodegeneration [5]. Activated T cells and
microglia secrete TRAIL, which acts as a death signal on
neurons and susceptible oligodendrocytes [5,6,7]. Furthermore,
excitotoxicity and oxidative stress play a major role as mediators
of axonal damage [8]. However, currently approved treatments
focus primarily on immunomodulation, and are only partially
effective. Thus, new therapeutic strategies that include neuro-
protective as well as neuroregenerative aspects are required. One
promising strategy is the use of combination therapies based on
drugs that may complement one another in order to provide
additive benefit [9].
Glatiramer acetate (GA, Copaxone, Copolymer 1) is an
immunomodulatory agent for treatment of relapsing-remitting
MS. GA is a synthetic basic random copolymer composed of
tyrosine, glutamate, alanine and lysine that induces GA-specific
Th2 cells which secrete anti-inflammatory cytokines in the CNS
through cross-recognition with myelin autoantigens [10]. Recent-
ly, it has been shown that GA promotes neurogenesis, neuropro-
tection and remyelination in MS lesions mediated by neurotrophic
factors such as brain-derived neurotrophic factor (BDNF),
Neurotrophin 3 and Neurotrophin 4 produced by GA-specific
Th2 cells [11,12,13]. New studies also indicate that GA can induce
anti-inflammatory type II monocytes, that are characterized by
increased secretion of interleukin (IL)-10 and decreased produc-
tion of IL-12 and that can direct differentiation of Th2 cells and
CD4+CD25+FoxP3+ regulatory T cells [14].
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25456We have recently shown that epigallocatechin-3-gallate
(EGCG), the main phenol of green tea, can reduce clinical
severity of EAE by both limiting brain inflammation and reducing
neuronal damage [15]. EGCG is capable of protecting against
neuronal damage by directly blocking the formation of reactive
oxygen species in neurons as well as through iron chelating and
anti-apoptotic functions [15,16,17].
In light of the immunomodulatory and neuroprotective
properties of GA and EGCG we hypothesized an additive or
synergistic protective effect of GA and EGCG in inflammation as
well as in neuroprotection in vitro and in vivo in the animal model of
MS. Moreover, we wanted to know whether the combined
application of the two substances was safe, in order to be able to
start a treatment trial in patients.
Combination therapy of GA and EGCG synergistically reduced
neuronal cell death and promoted axonal outgrowth of primary
neurons. These effects could be translated into the EAE model in
which diminished clinical disease severity was associated with
reduced CNS inflammation in a synergistic manner. These results
strengthen the prospects of EGCG as an adjunct and well-
tolerated therapy for neuroinflammatory diseases, and underscore
the importance of evaluating combined anti-degenerative and
anti-inflammatory treatments.
Materials and Methods
Ethical Considerations
Animals were housed in the animal facility of the Neuroscience
Research Center of the Charite ´ Universita ¨tsmedizin Berlin.
Experimental procedures were approved by the regional animal
study committee of Berlin (LAGeSo approval ID G0147/05). All
animal work was conducted in accordance to national and
international guidelines to minimize discomfort to animals.
CNS cell death assays
For assessment of viability, hippocampal HT22 cells were
seeded at 5,000 cells per well in 96 well plates and cultured for
24 h. On the following day, cells received fresh medium and were
incubated with 10 mg/ml EGCG, 50 mg/ml GA, or both
compounds for 2 h before incubation with 5 mM glutamate. In
parallel, glioblastoma LN18 cells were cultured at 30,000 cells per
well along with 10 mg/ml EGCG and/or 12.5 mg/ml GA, and cell
death was induced by incubation with TRAIL (20 ng/ml, Alexis,
San Diego, CA) and TRAIL enhancer (2 mg/ml). The crystal
violet assay was performed 16 h thereafter as previously described
[15]. Briefly, cells were stained for 30 min with 0.5% crystal violet
in 20% methanol. After washing and drying overnight, crystal
violet was dissolved in 50 ml/well of 0.1 M sodium citrate solution
diluted in 50% ethanol and subsequently quantified photometri-
cally by absorbance at 550 nm (Dynatech Laboratories, Chantilly,
VA). Values are expressed as the percentage of survival compared
with untreated controls.
Axonal outgrowth assay
Entorhinal cortex slices were prepared at postnatal day 2 from
mouse brains as previously described [18,19]. In brief, after
decapitation the entorhinal cortex was dissected in ice-cold
preparation medium (minimal essential medium with 2 mM L-
glutamine and 8 mM Trisbase) [20]. Transverse slices of 350 mm
were cut using a tissue chopper. Entorhinal slices were embedded
in 30 ml of collagen drops and placed on a glass slide. The
preparations were incubated with 5 mg/ml EGCG, 6.25 mg/ml
GA, or both compounds together. To evaluate axonal outgrowth
from the explants we used a protocol utilizing image analysis
software (Image J, Wayne Rasband, NIH, as described previously
[21,22]. In brief, axonal density and number of axons were
quantified after 2 days of culture, and photo-documented at a total
magnification of 1006, Olympus LCPLANFL objective (Olympus
IX70, Hamburg, Germany) [23]. Image processing was based on
an edge detection algorithm, the Sobel operator, which performs a
2-dimensional spatial gradient measurement in a microphoto-
graph to detect regions of high spatial density that correspond to
neurites. To determine the axonal density, the mean intensity was
calculated in a standardized area parallel to the brain slice margin
of every single brain slice [23]. The number of axons was
measured by quantifying all intersections of axons with a
standardized line parallel to the brain slice border. Supernatants
were reserved from the slice cultures and analyzed for neurotro-
phins by Enzyme-Linked Immunosorbent Assay (ELISA), accord-
ing to the manufacturer’s directions (Promega, Mannheim
Germany). The limit of detection was 31.2 and 15.6 pg/ml for
glial cell derived neurotrophic factor (GDNF) and BDNF,
respectively.
Induction and treatment of EAE
6–8 week old female SJL/L mice (Charles River Laboratories,
Sulzfeld, Germany) were immunized s.c. with 250 mgo f
proteolipid protein (PLP) peptide 139–151 (purity .95%;
Pepceuticals, Leicester, UK) emulsified in an equal volume of
PBS and complete Freund’s adjuvant containing 6 mg/ml
Mycobacterium tuberculosis H37Ra (Difco, Franklin Lakes, NJ).
200 ng of Bordetella pertussis toxin (List Biological Laboratories,
Campell, CA) was administered i.p. at day 0 and 2. For preventive
treatment, EGCG (Sigma-Aldrich, Deisenhofen, Germany) was
dissolved in 0.9% NaCl. 300 mg of EGCG or vehicle (0.9% NaCl)
were given by oral gavage twice daily from day-9 before
immunization on. 50 mg GA (TEVA) or vehicle (Mannitol 4%)
was dissolved in PBS, emulsified in incomplete Freund’s adjuvant
(Difco) and injected s.c. once on day 27. Therapeutic treatment
with 300 mg of EGCG or vehicle twice daily, and with 150 mgG A
or vehicle once daily, was started after animals reached a clinical
score$2.
Mice were monitored daily for clinical symptoms and scored as
follows: 0=no disease; 1=complete tail paralysis; 2=hind limb
paraparesis; 3=bilateral hind limb paraplegia; 4=complete
forelimb and hind limb paraplegia; 5=moribund or dead animals.
Histology
Spinal cords from mice transcardially perfused with 4%
paraformaldehyde were postfixed overnight, cryoprotected suc-
cessively in 15% and 30% sucrose and cut into 8 cross-sectional
segments. The segments were embedded together in Cryo-Embed
(Ax-lab), frozen in a methylbutane/dry ice mixture and cut into
12 mm sections with a cryostat. Hematoxylin and eosin stained
sections were examined by light microscopy for the presence of
inflammation, using a Zeiss Observer.Z1 microscope with a Zeiss
AxioCam MRm camera. Semi-quantitative assessment was done
by counting the number of quadrants with inflammatory infiltrates
for each of the 8 segments. Quadruplicate sections for each mouse
were assessed in a blinded manner and data are presented as the
percentage of total quadrants positive for inflammatory infiltrates.
Statistics
EAE disease courses, histology scores, and cumulative disease
activity were analyzed with the non-parametric Kruskal-Wallace
ANOVA with the Dunn’s post-hoc test, and the Mann-Whitney
test. The cell death and axonal outgrowth assays were analyzed
with 1-way ANOVA with the Bonferroni correction. Time to
Neuroprotection in Neuroinflammation
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Bonferroni correction for multiple comparisons. GraphPad Prism
4 (GraphPad Software, San Diego CA) was used for the analysis.
p-values,0.05 were considered significant (* p,0.05; ** p,0.01;
*** p,0.001).
Results
EGCG and GA in combination inhibit death of CNS cells in
vitro
We asked whether the combination of EGCG and GA could
havean additiveor synergistic effect inpreventing neuronal damage
in mouse and human CNS cell lines. Therefore, we induced
neuronal cell death through two mechanisms, which are known to
contribute to neuronal damage in neuroinflammation, glutamate-
promoted excitotoxicity and TRAIL-mediated apoptosis.
We induced excitotoxicity by incubation of murine hippocampal
HT22 cells with glutamate. We preincubated the cells with different
concentrations of EGCG and GA and established suboptimal doses
of EGCG (10 mg/ml) or GA (50 mg/ml). Suboptimal doses of
EGCG and GA showed little or no neuroprotective effect compared
to control, whereas the combination of 10 mg/ml EGCG and
50 mg/ml GA significantly increased survival of HT22 cells
compared to controls, as determined by the crystal violet assay
(Fig. 1A). Thus, the effect of the combination therapy was found to
be synergistic compared to EGCG and GA alone.
To examine whether the combination therapy is also protective
in a caspase-dependent apoptotic pathway, we induced TRAIL-
mediated cell death in susceptible human glioblastomal LN18
cells. Again, the combination of EGCG (10 mg/ml) and GA
(12.5 mg/ml) showed a statistically significant increase in cell
survival compared to control. Conversely, EGCG or GA alone did
not induce a significant increase (Fig. 1B).
EGCG and GA promote axonal growth and density in
vitro
We next investigated whether EGCG and GA stimulate
neuroregeneration using an axonal outgrowth model of entorhinal
cortex explants. The explants were embedded in a three-
dimensional collagen gel matrix with 5 mg/ml EGCG or
6.25 mg/ml GA alone or with the combination of 5 mg/ml EGCG
and 6.25 mg/ml GA. The density of the outgrowing neurites was
photo-documented at higher magnification and quantified
(Fig. 2A). Axonal density was quantified by measuring the mean
intensity in a standardized area parallel to the brain slice margin.
The total number of axons increased significantly in the
presence of EGCG and GA in combination compared to control
brain slices (Fig. 2B). GA or EGCG alone did not induce a
significant increase in the number of neurites.
Axons in slices treated with both GA and EGCG showed a
significantly higher density compared to brain slices under control
conditions. Again, there was no significant effect of EGCG or GA
alone (Fig. 2C). Thus, the combination of EGCG and GA showed
a synergistic effect on axonal growth and density compared to
EGCG and GA alone. In addition, GA induced the secretion of
BDNF and GDNF, which was detected in the supernatants of the
brain slice culture by ELISA. No additional increase was seen with
EGCG (Fig. 2D, E).
Combination therapy with EGCG and GA delays disease
onset and synergistically reduces EAE severity
Next, we tested whether these neuroprotective and neuroregen-
erative effects of EGCG and GA in vitro could translate into an
additive or synergistic clinical benefit in the animal model of
autoimmune neuroinflammation, EAE. In order to evaluate
combination therapyinEAEusingmedicationsthatareindividually
effective, it is necessary to test these drugs in combination using
suboptimal doses of at least one drug. Therefore, SJL/L mice with
EAE were treated with known suboptimal doses of GA (50 mg)
supplemented with 600 mg EGCG [24].
For preventive treatment, EGCG was given orally twice daily
starting nine days before EAE induction, and GA was injected s.c.
in incomplete Freund’s adjuvant once seven days before
immunization with PLP139–151. As expected, treatment with
suboptimal doses of GA alone did not significantly decrease
disease incidence and severity. However, the combination therapy
significantly reduced the severity of relapsing-remitting EAE and
synergistically delayed the onset of disease compared to vehicle
treated animals (Fig. 3A,B). The treatment effect of the
combination therapy was also found to be synergistic compared
Figure 1. EGCG and GA in combination inhibit death of CNS
cells in vitro. Survival of murine HT22 neuronal cells (A) and human
glioblastomal LN18 cells (B) was determined in a crystal violet assay
after induction of apoptosis by incubation with Glutamate (5 mM) (A) or
TRAIL (20 ng/ml) (B). EGCG (10 mg/ml) and/or GA (12.5 mg/ml) were
added to the culture 2 h before apoptosis induction, *p,0.05,
**p,0.001, representative of 2 experiments.
doi:10.1371/journal.pone.0025456.g001
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observation. The cumulative disease activity (calculated as the area
under the curve of the clinical score plots for each individual
animal [25]), was significantly lower in the combined EGCG and
GA group, as compared to the vehicle treated, and appeared
synergistic compared to the single treatment groups (Fig. 3C).
Additionally, all animals were closely monitored for adverse
clinical events, such as rapid worsening of symptoms or
anaphylaxis, or for signs of atypical EAE (ie. ataxia), although
none of these events occurred.
Figure 2. EGCG and GA promote axonal growth and density in vitro. Representative photomicrographs of brain slices with axonal outgrowth
after addition of EGCG (5 mg/ml), GA (6.25 mg/ml) and the combination of EGCG (5 mg/ml) and GA (6.25 mg/ml) are shown. 1006magnification, scale
bar: 300 mm (A). The number of axons was measured by quantifying all intersections of axons with a standardized line parallel to the brain slice
border, **p,0.001 (B). The density of outgrowing axons was determined by measuring the mean intensity in a standardized area parallel to the brain
slice edge, **p,0.001 (C). Levels of GDNF (D) and BDNF (E) were measured in the supernatant of outgrowth assays by ELISA, n.d.=not detectable.
**p,0.001 ***p,0.0001.
doi:10.1371/journal.pone.0025456.g002
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disability in established EAE
For the treatment of patients suffering from MS it is important
to know whether the combined treatment could have a protective
effect in established disease. For this therapeutic paradigm,
treatment was initiated when all mice showed a clinical score$2.
EGCG (300 mg) was given twice daily, and GA (150 mg) was
injected subcutaneously daily. The combination therapy enhanced
recovery and prevented long-term neurological deficits, as
indicated by significant reductions in the mean clinical score
(Fig. 4A) and the cumulative disease activity compared to the
vehicle treated group (Fig. 4B). Again, no adverse events occurred
in the combination therapy group during the observation period.
EGCG and GA together ameliorate CNS inflammatory
pathology
We then examined whether the synergistic protective effects of
the preventive EGCG and GA treatment on EAE clinical scores
would be reflected in the CNS inflammatory pathology.
Histological examination revealed extensive inflammatory lesions
throughout the spinal cord in control mice. While some reduction
in the histopathology could be seen in both the EGCG and GA
single treated groups, this effect was synergistic in the combination
treatment group (Fig. 5A). Upon quantification of the extent of
inflammation, only the combined EGCG and GA treated group
showed a statistically significant reduction in histopathology,
compared to the control (Fig. 5B).
Discussion
GA is one of the most common immunomodulatory therapies
for MS. In addition to the inflammatory components of the
pathology, neurodegeneration, axonal damage and deficits in
neuroregeneration are important aspects of the disease and should
be taken into consideration as targets for therapeutic approaches.
Thus, we investigated the potential of the combination therapy of
GA and the previously tested neuroprotective agent EGCG.
We showed a synergistic effect of the combination therapy of
EGCG and GA on neuronal survival and axonal growth in vitro.
No unexpected adverse events occurred when applying the two
substances together. Importantly, we also found that the
combination therapy not only delayed EAE onset and reduced
severity when applied to prevent disease, but was also effective in
the treatment of established EAE symptoms in vivo.
Figure 3. Combination therapy with EGCG and GA delays disease onset and synergistically reduces EAE severity. For preventive
treatment EGCG (300 mg) or vehicle (NaCl 0.9%) was administered orally twice daily from day 29 before immunization with PLP139–151 until day 45.
GA (50 mg) or vehicle (Mannitol 4%) in incomplete Freund’s adjuvant was given s.c. once on day 27 before immunization. Mean disease score of
control, EGCG, GA and the combination therapy group is shown from day 0 to day 45 after immunization (A), * p,0.05 day 13,15–18,20–22,24,26–27,
**p,0.01 day 14,19,23,25,28,35–39,42, n=8 per group. Onset of disease in control, GA, EGCG and combination therapy group is presented in a
Kaplan-Meier survival curve as percentage of sick mice at a certain day after immunization (B), *p,0.05. Cumulative disease activity of control, GA,
EGCG and combination therapy group was calculated as the area under the curve of the clinical score plots for each individual animal (C), *p,0.05.
doi:10.1371/journal.pone.0025456.g003
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neuroinflammatory diseases such as MS. Several mechanisms have
been shown to contribute to neuronal damage in neuroinflamma-
tion, such as TRAIL-mediated apoptosis and glutamate-promoted
excitotoxicity. We previously reported that the death ligand
TRAIL critically contributes to irreversible CNS damage during
autoimmune neuroinflammation [6,7,26], and demonstrated that
functional blocking of TRAIL was effective in preventing caspase-
dependant neuronal death in EAE [5]. Thus, as shown here in vitro
the combination of EGCG and GA might decrease TRAIL-
induced damage of neurons and oligodendrocytes in neuroin-
flammatory diseases.
Increase in extracellular glutamate by activated microglia
during neuroinflammation can have serious consequences, as it
is capable of precipitating excitotoxic cell death of neurons and
oligodendrocytes by overstimulation of ionotropic glutamate
receptors [27]. It has been previously shown, that targeting
glutamate excitotoxicity by treatment with the AMPA/kainate
antagonist NBQX resulted in substantial amelioration of EAE,
increased oligodendrocyte survival and reduced axonal damage
[28]. The ability of GA and EGCG in combination to effectively
and synergistically reduce excitotoxicity in vitro might as well
translate into reduced neuronal damage during EAE and MS.
Both our previous study [15] and other studies [29] have shown
that neuroprotective effects of EGCG are mediated, at least in
part, by reduced reactive oxygen species generation and reduction
in NFkB activity.
The mechanisms underlying GA-mediated neuroprotection
involve triggering T cell reactivation and inducing T cells to
switch to a protective phenotype [30]. So far there is evidence
suggesting that GA can also exert neuroprotection independently
of T cells, which seems to be mediated through protein kinase C
and BDNF [31]. Thus, our results in a T cell free system provide
further evidence for a direct neuroprotective mechanism of GA in
addition to T cell protective immunity.
It has been shown that multiple endogenous repair mechanisms
become activated after damage to the central nervous system in
the context of traumatic injury, neurodegenerative or neuroin-
flammatory diseases. These include repopulation of damaged
tissue by precursor cells for neurons and oligodendrocytes, and
Figure 4. Combination therapy with EGCG and GA alleviates disability in established EAE. For treatment of acute disease PLP139–151-
induced EAE mice were randomized into two groups after reaching a disease score of 2 and subsequently received 300 mg of oral EGCG or vehicle
(0.9% NaCl) twice daily in addition to daily s.c. injections of 150 mg GA or vehicle (4% Mannitol). Mean disease score of control and combination
therapy group is shown from day 0 to day 44 after immunization (A), *p,0.05 day 19, 20, 23, 24, 34, n=6. Cumulative disease activity of control and
combination therapy group was calculated (B), *p,0.05.
doi:10.1371/journal.pone.0025456.g004
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collaterals, formation of new synapses and axonal regeneration.
However, these endogenous self-repair mechanisms are not
sufficiently effective to reverse the damage that occurs in severe
or chronic disease. In MS, where demyelination and axonal
damage are major hallmarks of the disease, some efforts have been
made in developing regenerative therapies that further promote
remyelination, but very few studies focus on promotion of axonal
growth and regeneration [32,33]. Here we showed for the first
time that the immunomodulatory agent GA is able with EGCG to
directly promote axon outgrowth and increased axonal thickness
in primary neurons in a synergistic manner. It has been
demonstrated that GA-specific T cells induce bystander effects
on CNS resident cells to express beneficial cytokines, and
augments the in situ expression of BDNF, Neutrophin 3 and
Neural Growth Factor, which regulate axonal growth [13,34].
Here we observed that GA induced the production of neurotro-
phins in the supernatants of the entorhinal explant cultures
independent of GA-specific T cells. However, the effect of EGCG
in promoting axonal growth is not mediated by neutrophins as
neurotrophin levels were not increased upon combination therapy
compared to GA alone.
In our previous study we demonstrated a clear disease-limiting
effectofEGCGinEAE[15].In thepreventative paradigmthiseffect
reached statistical significance after 30 days of treatment, and after
50 days in the therapeutic paradigm [15]. The results of the present
study show that when combined with GA, the effects of EGCG were
even more potent, as statistically significant reductions in disease
scores were seen much earlier and disease severity and incidence
were reduced in a synergistic manner. The effects on clinical scores
were also reflected in a synergistic amelioration of CNS inflamma-
tory pathology. Even more important for clinical application, the
combination therapy of EGCG and GA also reduced severity of
disease when treatment started after onset of symptoms.
An increasing body of evidence indicates that cumulative axonal
loss in MS correlates with permanent clinical disability and that
Figure 5. EGCG and GA together ameliorate CNS inflammatory pathology. Representative Hematoxylin and Eosin staining of transverse
spinal cord sections of vehicle, EGCG, GA and EGCG and GA treated EAE mice is shown (A). 1006magnification, scale bar 500 mm. Inflammation in
standardized areas of the spinal cord of all treatment groups was assessed and is presented semi-quantitatively as percentage of spinal cord
quadrants with inflammatory foci relative to all assessed quadrants (B), *p,0.05, n=8 per group.
doi:10.1371/journal.pone.0025456.g005
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is a clear need for improved therapies that are aimed at providing
neuroprotection and preventing the progression of disease to
chronic disability. The synergistic immunomodulatory, neuropro-
tective and newly established neuroregenerative functions of
EGCG and GA as well as their excellent clinical tolerability make
these agents attractive therapeutic candidates for combination
therapy for MS. The fact that GA and EGCG act via distinct
mechanisms (immune modulation and neurotrophin production
versus antioxidant and metal ion chelating actions, respectively),
could explain the shown synergistic effects in vitro and in vivo.
Additionally, there is evidence indicating that EGCG has the
capacity to cross the blood-brain barrier [36,37]. This would be
important for exerting therapeutic benefits in the CNS in the
chronic phase of MS, when acute inflammation plays less of a role
in disease progression.
Thus, the combination therapy of GA and EGCG is a
promising and safe approach for MS as the therapeutic effects of
the already established agent GA might be enhanced by the
neuroprotectant EGCG. The beneficial effects of EGCG and GA
could also be relevant for other chronic neurodegenerative
diseases, as Alzheimer’s and Parkinson’s disease; thus combination
therapy with these compounds could have even broader clinical
implications.
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